Conferences

AIDS 2022

The 24th International AIDS Conference (AIDS 2022) took place in Montréal, Canada and virtually from 29 July to 2 August. NAM aidsmap was an official scientific media partner for the conference.
The search for a cure

Barcelona woman controls HIV for over 15 years without treatment

The search for a cure

California man appears to be another person cured of HIV after a stem cell transplant

PrEP programmes & uptake

Key population-led services now account for the majority of Thai PrEP users

Confidentiality, consent & medical ethics

The ethics of phylogenetics? Central issues surrounding the use of molecular HIV surveillance

Improving HIV care

Community-led monitoring of HIV services leads to investment and policy change

TB epidemiology

Zambian patients on dolutegravir and recycled tenofovir regimens have high risk of TB even after switch

Antibody-based prevention

Giving antibodies to prevent vertical transmission in Africa would be cost-effective or even save money, study finds

Access to healthcare

Community organisations have formed the backbone of the HIV response in Ukraine

Child developmental issues

Long-term Canadian study shows HIV-exposed children have worse health outcomes

Injectable & long-acting HIV treatment

Long-acting cabotegravir and rilpivirine may be feasible for people without viral suppression

The search for a cure

A cure must be a cure for all: why more HIV cure research in Africa is needed

Mental & emotional health problems

Social support can buffer the effects of stigma on suicidality among young people living with HIV

Improving HIV care

Package of person-centred care improves viral suppression for young people living with HIV in Kenya and Uganda

Undetectable viral load & treatment as prevention

The challenges integrating U=U into HIV care around the world

Child developmental issues

Rate of neural tube defects is no higher on dolutegravir

The search for a cure

We still have no HIV cure. But we have a better strategy for finding one

Elimination of hepatitis C

Broader hepatitis C treatment not leading to more reinfections in people with HIV

Transgender people

Injectable PrEP is just as effective for transgender women as it is for gay men, study analysis finds

Injectable & long-acting HIV treatment

New formulations and alternative injection sites might allow self-administration of long-acting cabotegravir and rilpivirine

Migrants, refugees & displaced people

Early response to Ukrainian refugees enabled continuity of HIV care, but longer-term issues must be addressed as war drags on

Finance & funding

Second-line treatment nearly nine times more expensive than first-line in upper-middle income countries

Harm reduction

Pilot harm reduction programmes in Africa show progress, despite challenging laws and policies

Improving HIV care

Virtually no screening and treatment for mental health disorders in many HIV clinics across the world

Improving HIV care

In Africa, ‘the heart of HIV stigma’ is within healthcare settings

Low CD4 count

What will it take to end advanced HIV disease-related deaths?

Coronavirus

People with HIV still at higher risk of death from COVID-19 in Omicron wave

Mpox (monkeypox)

Stronger monkeypox response needed in both the global North and Africa

PrEP science

New data suggest PrEP in pregnancy is safe

Injectable & long-acting PrEP

Injectable PrEP can only cost a little more than oral PrEP if it is to be cost-effective, South African study finds

Access to healthcare

Just six injections a year can prevent HIV: here’s what it will take for the world to afford them

Violence

Adolescents and women who experience violence more likely to get HIV and less likely to control it

Support issues for children & young people

‘Flourishing’ is a social determinant of health for children and young people

Drug-resistant TB

Oral six-month treatment for MDR-TB is safe and effective in people with HIV

Transgender people

Trans people left out of many countries’ strategic HIV plans

PrEP programmes & uptake

Who, what, where and when: tailoring PrEP services to increase uptake

TB transmission & prevention

HIV test-and-treat reduces TB incidence in the community

The search for an HIV prevention vaccine

Minimal antibody response in Imbokodo compels change of course for HIV vaccine research

Hepatitis B

Biktarvy combination pill may be most effective option for people with HIV and hepatitis B

Human rights

Educating police on harm reduction can help to prevent HIV and fatal overdoses

The search for a cure

Smart new single-cell assay shines a light on the HIV reservoir

PrEP programmes & uptake

PrEP inequities have worsened in the US over the last decade, both racially and regionally

HIV treatment for children & young people

Six-country study shows dolutegravir-based treatment is highly effective in children and adolescents

Undetectable viral load & treatment as prevention

Gaps in U=U awareness globally: healthcare providers need to do more to get the message out

Weight gain & lipodystrophy

Weight gain on treatment: more evidence that TAF plus dolutegravir leads to greater gains

Hepatitis C transmission & prevention

Widespread PrEP use is not leading to more hepatitis C transmission among gay and bisexual men

Generic medicines

ViiV Healthcare to allow 90 countries to access generic versions of HIV prevention shot

Sexually transmitted infections prevention

Taking antibiotic after sex cuts STIs by two-thirds, ‘DoxyPEP’ study finds

Interviews

AIDS 2022: 15 years post-treatment control of HIV

1 August 2022

At AIDS 2022, Dr Núria Climent & Dr José Alcamí from Hospital Clínic de Barcelona talk about a woman in Barcelona who has maintained an undetectable HIV viral load for more than 15 years after stopping antiretroviral therapy.

AIDS 2022: Antibiotics to prevent STIs

1 August 2022

At AIDS 2022, Professor Annie Luetkemeyer and Professor Connie Celum talk about taking antibiotics (doxycycline) to prevent STIs.

AIDS 2022: HIV remission after a stem cell transplant

2 August 2022

At AIDS 2022, Dr Jana Dickter talks about the 'City of Hope patient', a man from California who appears to have been cured of HIV after a stem cell transplant.

AIDS 2022: Intimate partner violence

2 August 2022

At AIDS 2022, Professor Lucie Cluver from the University of Cape Town talks to NAM's Roger Pebody about violence and HIV.

Conference bulletins

English

AIDS 2022: Taking antibiotic after sex cuts STIs by two-thirds, ‘DoxyPEP’ study finds, Sunday 31 July 2022

(HTML)

AIDS 2022: Barcelona woman controls HIV for over 15 years without treatment, Monday 1 August 2022

(HTML)

AIDS 2022: California man appears to be cured of HIV after stem cell transplant, Tuesday 2 August 2022

(HTML)

AIDS 2022: Just six injections a year can prevent HIV: how will the world afford them? Wednesday 3 August 2022

(HTML)

AIDS 2022: Could long-acting injectable cabotegravir and rilpivirine be self-administered? Tuesday 9 August 2022

(HTML)

Spanish

AIDS 2022: Un tratamiento con un antibiótico tras las relaciones sexuales reduce en dos tercios las ITS, según el estudio ‘DoxyPEP’, Domingo, 31 de julio de 2022

(HTML)

AIDS 2022: Una mujer en Barcelona consigue controlar el VIH durante más de 15 años sin tratamiento, Lunes, 1 de agosto de 2022

(HTML)

AIDS 2022: Un hombre de California parece haberse curado del VIH tras un trasplante de células madre, Martes, 2 de agosto de 2022

(HTML)

AIDS 2022: Con solo seis inyecciones al año se puede prevenir el VIH: ¿Cómo lo podrá costear el mundo?, Miércoles, 3 de agosto de 2022

(HTML)

AIDS 2022: ¿Podría autoadministrarse la formulación inyectable de acción prolongada de cabotegravir y rilpivirina? Martes, 9 de agosto de 2022

(HTML)

Portuguese

AIDS 2022: Tomar antibiótico depois do sexo reduz as IST em dois terços, segundo o estudo 'DoxyPEP', Domingo, 31 de julho de 2022

(HTML)

AIDS 2022: Mulher de Barcelona controla VIH há mais de 15 anos sem tratamento, Segunda-feira, 1 de agosto de 2022

(HTML)

AIDS 2022: Homem da Califórnia aparentemente curado do VIH após transplante de células estaminais, Terça-feira, 2 de agosto de 2022

(HTML)

AIDS 2022: Apenas seis injeções por ano podem prevenir o VIH: como podem os países pagar? Quarta-feira, 3 de agosto de 2022

(HTML)

AIDS 2022: Cabotegravir e rilpivirina injetáveis de ação prolongada podem ser autoadministrados? Terça-feira, 9 de agosto de 2022

(HTML)

Italian

AIDS 2022: Antibiotico assunto dopo il sesso riduce le IST di due terzi, rivela lo studio ‘DoxyPEP’, Domenica 31 luglio 2022

(HTML)

AIDS 2022: Donna di Barcellona in remissione HIV da oltre 15 anni senza gli antiretrovirali, Lunedì 1 agosto 2022

(HTML)

AIDS 2022: Uomo in California apparentemente curato dall’HIV dopo trapianto di staminali, Martedì 2 agosto 2022

(HTML)

AIDS 2022: Basterebbero sei iniezioni l’anno per prevenire l’HIV: come farà il mondo a permettersele? Mercoledì 3 agosto 2022

(HTML)

AIDS 2022: Cabotegravir e rilpivirina in formulazione iniettabile a lunga durata d’azione: sarà possibile l’autosomministrazione? Martedì 9 agosto 2022

(HTML)

Russian

СПИД 2022: Прием антибиотика после сексуального контакта сокращает уровень ИППП на две трети - по данным «DoxyPEP» исследования, Воскресенье, 31 июля 2022 г.

(HTML)

СПИД Конференции 2022: Жительница Барселоны без лечения контролирует ВИЧ на протяжении более 15 лет, Понедельник, 01 августа 2022 г.

(HTML)

СПИД Конференции 2022: Калифорнийский пациент вылечен от ВИЧ-инфекции после трансплантации стволовых клеток крови, Вторник, 2 августа 2022 г.

(HTML)

СПИД 2022: Всего шесть инъекций в год могут предотвратить ВИЧ-инфекцию: но как нам их получить? Среда, 3 августа 2022 г.

(HTML)

СПИД 2022: Будет ли возможно самостоятельно вводить инъекции пролонгированных каботегравир и рилпивирин? Вторник, 9 августа 2022 г.

(HTML)

French

AIDS 2022: La prise d’antibiotiques après des rapports sexuels réduit le nombre d’IST de deux-tiers, selon l’étude “DoxyPEP”, Dimanche 31 juillet 2022

(HTML)

AIDS 2022: Une femme de Barcelone contrôle son VIH pendant plus de 15 ans sans traitement, Lundi 1er aout 2022

(HTML)

AIDS 2022: Un Californien semble guéri du VIH après une greffe de cellules souches, Mardi 2 aout 2022

(HTML)

AIDS 2022: Six injections par an sont suffisantes pour prévenir le VIH : comment le monde pourra-t-il les financer ? Mercredi 3 aout 2022

(HTML)

AIDS 2022 : Peut-on s'injecter soi-même le cabotégravir et la rilpivirine injectables à action prolongée ?, Mardi 9 aout 2022

(HTML)